Pharvaris NV Stock Quote PHVS - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

21.09

Bid

19.57

Ask

23.18

Volume

249,603

20.40 Day's Range 21.38

15.00 52 Week Range 33.00

Market Cap

1.103B

Previous Close

20.26

Open

20.46

Last Trade

1801

21.09

Last Trade Time

16:00:00

Financial Volume

$ 5,147,434

VWAP

20.6225

Average Volume (3m)

74,086

Shares Outstanding

52,290,212

Dividend Yield

PE Ratio

-10.89

Earnings Per Share (EPS)

-1.93

Revenue

Net Profit

-100.88M

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.pharvaris.com

Headquarters

Leiden, South Holland, Nld

Founded

Pharvaris NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PHVS. The last closing price for Pharvaris NV was $20.26. Over the last year, Pharvaris NV shares have traded in a share price range of $ 15.00 to $ 33.00.

Pharvaris NV currently has 52,290,212 shares outstanding. The market capitalization of Pharvaris NV is $1.06 billion. Pharvaris NV has a price to earnings ratio (PE ratio) of -10.89.

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by...

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Extension data confirm the observed safety and tolerability profile from Phase 2 studies and further support the potential for deucrictibant to become a preferred therapy for the management of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.35	1.68756027001	20.74	21.22	20.08	100077	20.66647904	CS
4	3.2	17.8870877585	17.89	21.54	17	125120	19.19471832	CS
12	2.61	14.1233766234	18.48	21.54	15.5	74086	18.5199016	CS
26	-3.76	-15.1307847082	24.85	26.565	15.37	71740	19.61989228	CS
52	2.69	14.6195652174	18.4	33	15	91686	23.01031049	CS
156	3.37	19.0180586907	17.72	33	1.77	223248	12.34276245	CS
260	-3.91	-15.64	25	42.86	1.77	195287	13.14160246	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
LFLYLeafly Holdings Inc	$ 3.91 (118.44%)	4.77M
AENTAlliance Entertainment Holding Corporation	$ 2.82 (38.24%)	125.45k
TNONTenon Medical Inc	$ 6.22 (23.66%)	2.83M
AEMDAethlon Medical Inc	$ 0.48 (23.08%)	8.59M
LDTCLeddarTech Holdings Inc	$ 0.355 (19.13%)	200.93k
EJHE Home Household Service Holdings Ltd	$ 0.075 (-23.16%)	9M
JFBRJeffs Brands Ltd	$ 0.262 (-14.38%)	14.48k
KOPNKopin Corporation	$ 0.83 (-13.91%)	226.41k
NCINeo Concept International Group Holdings Ltd	$ 0.73 (-13.10%)	1.61M
ARQArq Inc	$ 5.59 (-9.40%)	88.29k
EJHE Home Household Service Holdings Ltd	$ 0.075 (-23.16%)	9M
AEMDAethlon Medical Inc	$ 0.48 (23.08%)	8.59M
HSTHost Hotels and Resorts Inc	$ 18.53 (0.00%)	6.45M
SQQQProShares UltraPro Short QQQ	$ 7.80 (0.52%)	5.43M
LFLYLeafly Holdings Inc	$ 3.92 (118.99%)	4.77M